NASDAQ: AXSM - Axsome Therapeutics, Inc.

Yield per half year: +15.32%
Sector: Healthcare

Company Analysis Axsome Therapeutics, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (88.83 $) is less than fair price (101.15 $)
  • The stock's return over the last year (24.9%) is higher than the sector average (-19.51%).
  • Current debt level 30.49% is below 100% and has decreased over 5 years from 44.81%.

Disadvantages

  • Dividends (0%) are below the sector average (0.5468%).
  • The company's current efficiency (ROE=-125.27%) is lower than the sector average (ROE=9.61%)

Similar companies

Alexion

ABIOMED

Amgen

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Axsome Therapeutics, Inc. Healthcare Index
7 days -4.1% -12.7% -2.3%
90 days -4% -27.8% 9.6%
1 year 24.9% -19.5% 31.2%

AXSM vs Sector: Axsome Therapeutics, Inc. has outperformed the "Healthcare" sector by 44.41% over the past year.

AXSM vs Market: Axsome Therapeutics, Inc. has significantly underperformed the market by -6.28% over the past year.

Stable price: AXSM is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: AXSM with weekly volatility of 0.4789% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 12.89

3.2. Revenue

EPS -5.27
ROE -125.27%
ROA -40.67%
ROIC -133.19%
Ebitda margin -65.07%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (88.83 $) is lower than the fair price (101.15 $).

Price not significantly lower than the fair price: The current price (88.83 $) is slightly lower than the fair price by 13.9%.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.89).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (18.27) is higher than that of the sector as a whole (4.82).

P/BV vs Market: The company's P/BV (18.27) is higher than that of the market as a whole (3.36).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (12.89) is lower than that of the sector as a whole (33.76).

P/S vs Market: The company's P/S indicator (12.89) is higher than that of the market as a whole (10.23).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-18.68) is higher than that of the sector as a whole (-22.15).

EV/Ebitda vs Market: The company's EV/Ebitda (-18.68) is lower than that of the market as a whole (28.27).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 50.06% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (50.06%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).

5.4. ROE

ROE vs Sector: The company's ROE (-125.27%) is lower than that of the sector as a whole (9.61%).

ROE vs Market: The company's ROE (-125.27%) is lower than that of the market as a whole (10.79%).

5.5. ROA

ROA vs Sector: The company's ROA (-40.67%) is lower than that of the sector as a whole (0.3443%).

ROA vs Market: The company's ROA (-40.67%) is lower than that of the market as a whole (6.51%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-133.19%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-133.19%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (30.49%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 44.81% to 30.49%.

Excess of debt: The debt is not covered by net income, percentage -74.96%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5468%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

Transaction date Insider Type Price Volume Quantity
09.08.2024 Jacobson Mark L.
Chief Operating Officer
Sale 84.26 4 022 490 47 739
09.08.2024 Jacobson Mark L.
Chief Operating Officer
Purchase 4.04 192 866 47 739

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Axsome Therapeutics, Inc.

9.3. Comments